These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 751798)

  • 21. Direct and indirect effects of insulin in suppressing glucose production in depancreatized dogs: role of glucagon.
    Giacca A; Fisher SJ; McCall RH; Shi ZQ; Vranic M
    Endocrinology; 1997 Mar; 138(3):999-1007. PubMed ID: 9048601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of selective insulin or glucagon deficiency on glucose turnover.
    Lickley HL; Ross GG; Vranic M
    Am J Physiol; 1979 Mar; 236(3):E255-62. PubMed ID: 426056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.
    Valverde I; Dobbs R; Unger RH
    Metabolism; 1975 Sep; 24(9):1021-8. PubMed ID: 1152674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia.
    Klaff LJ; Taborsky GJ
    Diabetes; 1987 May; 36(5):592-6. PubMed ID: 2883057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin and diabetes mellitus: the role of glucagon in diabetic hyperglycemia and glucose intolerance.
    Wahren J
    Scand J Clin Lab Invest; 1976 Oct; 36(6):497-503. PubMed ID: 1006141
    [No Abstract]   [Full Text] [Related]  

  • 26. Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo.
    Korányi L; Péterfy F; Szabó J; Török A; Guóth M; Tamás G
    Diabetes; 1981 Sep; 30(9):792-4. PubMed ID: 6114889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of gastrointestinal glucagon response to hypoglycaemia in depancreatized dogs.
    Matsuyama T; Tanaka R; Shima K; Nonaka K; Tarui S
    Diabetologia; 1978 Dec; 15(6):471-4. PubMed ID: 720780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.
    Greenbaum CJ; Havel PJ; Taborsky GJ; Klaff LJ
    J Clin Invest; 1991 Sep; 88(3):767-73. PubMed ID: 1679440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catecholamine responses and their interactions with other glucoregulatory hormones.
    Vranic M; Gauthier C; Bilinski D; Wasserman D; El Tayeb K; Hetenyi G; Lickley HL
    Am J Physiol; 1984 Aug; 247(2 Pt 1):E145-56. PubMed ID: 6147092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of extrapancreatic immunoreactive glucagon to intraluminal nutrients in pancreatectomized dogs.
    Ohneda A; Kobayashi T; Nihei J
    Horm Metab Res; 1984 Jul; 16(7):344-8. PubMed ID: 6386643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxytocin increases extrapancreatic glucagon secretion and glucose production in pancreatectomized dogs.
    Altszuler N; Puma F; Winkler B; Fontan N; Saudek CD
    Proc Soc Exp Biol Med; 1986 May; 182(1):79-83. PubMed ID: 3515351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of somatostatin on the hepatic extraction of insulin and glucagon in the anesthetized dog.
    Ishida T; Röjdmark S; Bloom G; Chou MC; Field JB
    Endocrinology; 1980 Jan; 106(1):220-30. PubMed ID: 7349954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of glucagon in the control of futile cycling as studied in alloxan-diabetic dogs.
    Lickley HL; Kemmer FW; el-Tayeb KM; Vranic M
    Diabetologia; 1987 Mar; 30(3):175-82. PubMed ID: 2884159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.
    Starke A; Imamura T; Unger RH
    J Clin Invest; 1987 Jan; 79(1):20-4. PubMed ID: 2878938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous hyperglycemia restores insulin release impaired by somatostatin analogue.
    Taborsky GJ; Porte D
    Am J Physiol; 1981 Apr; 240(4):E407-13. PubMed ID: 6111928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of phenformin upon the plasma pancreatic and gut glucagon-like immunoreactivity in diabetics.
    Czyzyk A; Heding LG; Malczewski B; Miedzinska E
    Diabetologia; 1975 Apr; 11(2):129-33. PubMed ID: 168107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus.
    Gerich JE; Lorenzi M; Karam JH; Schneider V; Forsham PH
    JAMA; 1975 Oct; 234(2):159-5. PubMed ID: 1242153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of phentolamine on the somatostatin-induced inhibition of glucagon and insulin secretion.
    Kaneto A; Kajinuma H; Kaneko T; Kosaka K
    Metabolism; 1978 Aug; 27(8):901-10. PubMed ID: 209286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of growth hormone on acute glucagon and insulin release.
    Sirek A; Vranic M; Sirek OV; Vigas M; Policova Z
    Am J Physiol; 1979 Aug; 237(2):E107-12. PubMed ID: 380363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.